Abstract: The present invention relates to biologically active compounds, particularly liquid compounds, which are immobilized on a solid carrier material, particularly on mesoporous silica. The compounds are non-covalently supported on the solid carrier material thereby forming stable, easily handled solids which have the further advantage that the adsorbed biologically active compounds have improved thermal stability compared with the non-adsorbed compounds, and that they are released rapidly and completely from the carrier material when placed in an aqueous environment.

Abstract: The present application relates to anti-LOX and anti-LOXL2 antibodies and their use in purification, diagnostic and therapeutic methods. Antibodies include monoclonal antibodies, humanized antibodies and functional fragments thereof. Anti-LOX and anti-LOXL2 antibodies can be used to identify and treat conditions such as a fibrotic condition, angiogenesis, or to prevent a transition from an epithelial cell state to a mesenchymal cell state.

Abstract: An optical device includes an array of optical elements located over a package substrate. A controller is also located over the package substrate. The controller is operable to control an operational state of the array in response to an optical signal detected by an optical receiver.

Abstract: This invention relates to a process for removing metals, particularly mercury, from hydrocarbon streams by use of an ionic liquid, where in the metal-containing hydrocarbon stream is contacted with an ionic liquid to produce a product hydrocarbon stream having reduced mercury content.

Abstract: The present invention is a novel process for the preparation of chalcogenone compounds by conversion of ionic liquids and salts comprising nitrogen-containing heterocyclic cations and basic anions to the corresponding nitrogen-containing heterocyclic chalcogenones by reaction with elemental chalcogens.

Abstract: The present application relates to anti-LOX and anti-LOXL2 antibodies and their use in purification, diagnostic and therapeutic methods. Antibodies include monoclonal antibodies, humanized antibodies and functional fragments thereof. Anti-LOX and anti-LOXL2 antibodies can be used to identify and treat conditions such as a fibrotic condition, angiogenesis, or to prevent a transition from an epithelial cell state to a mesenchymal cell state.

Abstract: The present disclosure provides lysyl oxidase-like-2 (LOXL2) polypeptide binding agents, including, for example, antibodies that specifically bind a LOXL2 polypeptide; and further provides compositions comprising same. The binding agents can be used in various treatment and diagnostic methods, which are also provided.

Abstract: An optical device includes an array of optical elements located over a package substrate. A controller is also located over the package substrate. The controller is operable to control an operational state of the array in response to an optical signal detected by an optical receiver.

Abstract: The present disclosure provides innovative methodology and related compositions and kits for preventing and treating various diseases associated with abnormal cell proliferation, angiogenesis and fibrosis, by using an inhibitor of processed forms of lysyl oxidase or lysyl oxidase-like proteins, an inhibitor of LOX and an inhibitor of a LOXL, or a synergistic combination of an inhibitor of LOX or LOXL combined with other therapeutic agents. Also provided are innovative methods for selecting agents that prevent or inhibit tumor invasion, angiogenesis and metastasis, by contacting cells that are in an epithelial-mesenchymal transition (EMT) state with a candidate agent and detecting a change in the EMT state of the cells. Methods and related compositions and kits for diagnosing or monitoring various diseases associated with abnormal cell proliferation, angiogenesis and fibrosis, by using molecules or agents that specifically recognize processed forms of LOX or LOXL are also provided.

Abstract: The present application relates to anti-LOX and anti-LOXL2 antibodies and their use in purification, diagnostic and therapeutic methods. Antibodies include monoclonal antibodies, humanized antibodies and functional fragments thereof. Anti-LOX and anti-LOXL2 antibodies can be used to identify and treat conditions such as a fibrotic condition, angiogenesis, or to prevent a transition from an epithelial cell state to a mesenchymal cell state.

Abstract: A printing system includes a printer and a first accessory device coupled to receive printed pages from the printer. The first accessory device contains a straight-through paper path and a reversing paper path. The straight-through paper path maintains the printed pages in the same order as received from the printer. The reversing paper path reverses the order of the printed pages received from the printer. The printing system also includes a second accessory device coupled to receive printed pages from the first accessory device.